Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2022-070
Huadong Medicine Co., Ltd.
The Third Quarterly Report 2022
The Company and all members of the Board of Directors hereby guarantee that the information
presented in this report is authentic, accurate and complete and free of any false records, misleading
statements or material omissions.
Important Declaration:
1. The Board of Directors, Board of Supervisors, directors, supervisors, and senior management of
Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the
information presented in this report is authentic, accurate, and complete and free of any false records,
misleading statements or material omissions, and shall undertake individual and joint legal liabilities.
2.TheCompany’s legal representativeandtheofficerin chargeofaccounting,andheadof accounting
department (accounting supervisor) hereby declare and guarantee that the financial statements in this
quarterly report are authentic, accurate, and complete.
3. Has the third quarterly report been audited
□ Yes No
This report is prepared both in Chinese and English. Should there be any discrepancy between the
Chinese and English versions, the Chinese version shall prevail.
I. Key financial data
(I) Key accounting data and financial indicators
Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data
□ Yes No
Change of the current Change of the first nine
The current reporting reporting period over First nine months of months of 2022 over
period the same period last 2022 the same period last
year year
Operating income 9,660,543,088.09 10.43% 27,858,507,079.10 7.45%
(yuan)
Net profit attributable
to listed-company 640,899,562.97 7.71% 1,981,470,047.95 4.54%
shareholders (yuan)
Net profit attributable
to listed-company
shareholders after 629,214,050.43 10.77% 1,901,053,230.06 7.89%
deducting non-
recurring gains/losses
(yuan)
Net cash flows from
operating activities — — 1,320,252,925.99 -37.31%
(yuan)
Basic earnings per 0.3663 7.71% 1.1324 4.54%
share (yuan/share)
Diluted earnings per 0.3663 7.71% 1.1324 4.54%
share (yuan/share)
Weighted average 3.62% -0.13% 11.39% -0.89%
return on equity (ROE)
End of the current End of last year Change of the end of the current reporting period
reporting period over the end of last year
Total assets (yuan) 30,662,572,819.67 26,996,403,366.69 13.58%
Total ownership
interest attributable to 18,068,711,890.05 16,579,374,323.08 8.98%
listed-company
shareholders (yuan)
Share capital of the Company as of the trading day before disclosure:
Share capital of the Company as of the trading day before 1,749,809,548.00
disclosure (shares)
Fully diluted earnings per share calculated on the basis of the latest share capital
Dividends paid on preferred shares 0.00
Perpetual bond interest paid (yuan) 0.00
Fully diluted earnings per share calculated on the basis of the 1.1324
latest share capital (yuan/share)
(II) Items and amounts of non-recurring gains/losses
Applicable □Inapplicable
Unit: RMB yuan
Item Amount in the current Amount in the first nine Note
reporting period months of 2022
Gains/losses on disposal of
non-current assets (including
the written-off part of the -6,456,222.42 2,413,541.61
accrued assets impairment
reserve)
Tax refund and reduction with 298,676.54 2,758,810.47
ultra vires examination and
approval or without official
approval documents
Government grants included
in current gains/lo
查看PDF原文
